Prasco enters marketing, distribution agreement with GSK

MASON, Ohio Prasco Labs announced Wednesday it has entered into a marketing and distribution agreement with GlaxoSmithKline.

FLONASE Nasal Spray will be the first product to be marketed under this agreement. Prasco, as GSK’s agent and on GSK’s behalf, will solicit orders for, and distribute, Fluticasone Propionate Nasal Spray to all trade classes in the United States under a GSK/Prasco label.

Fluticasone Propionate Nasal Spray is AB-rated, therapeutically equivalent and substitutable for the brand FLONASE Nasal Spray. Fluticasone Propionate is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older.

"We are especially proud to have established this relationship with GlaxoSmithKline, a global leader in the research-based pharmaceutical industry," said E. Thomas Arington, Prasco CEO. "We look forward to working with GSK to provide more choices for patients in the generics market."